Protara Therapeutics (TARA) Net Income towards Common Stockholders (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Net Income towards Common Stockholders of -$28.9 million for Q1 2026, down 58.4% year-over-year from -$69.5 million in Q1 2025, and down 48.42% quarter-over-quarter from -$19.5 million in Q4 2025.
Protara Therapeutics (TARA) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$28.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 58.4% year-over-year to -$28.9 million; the TTM figure through Mar 2026 stood at -$88.8 million (down 52.32% YoY), while the FY2025 annual figure was -$148.1 million, down 25.13% from the prior year.
- Net Income towards Common Stockholders eased to -$28.9 million in Q1 2026 per TARA's latest filing, from -$19.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $10.8 million in Q1 2022 and bottomed at -$39.0 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$15.8 million across 5 years, with a median of -$17.7 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 178.25% — and 2024, when it sank 270.9%.
- Protara Therapeutics' Net Income towards Common Stockholders stood at -$39.0 million in 2022, then surged by 73.77% to -$10.2 million in 2023, then decreased by 11.32% to -$11.4 million in 2024, then tumbled by 71.29% to -$19.5 million in 2025, then slumped by 48.42% to -$28.9 million in 2026.
- Business Quant data shows TARA's Net Income towards Common Stockholders at -$28.9 million in Q1 2026, -$19.5 million in Q4 2025, and -$19.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | -24.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.66 Mn |
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -19.49 Mn |
| Sep 30, 2025 | -19.37 Mn |
| Jun 30, 2025 | -20.98 Mn |
| Mar 31, 2025 | -18.26 Mn |
| Dec 31, 2024 | -11.38 Mn |
| Sep 30, 2024 | -17.69 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Mar 31, 2024 | -15.46 Mn |
| Dec 31, 2023 | -10.22 Mn |
| Sep 30, 2023 | -9.86 Mn |
| Jun 30, 2023 | -29.38 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | -38.97 Mn |
| Sep 30, 2022 | -7.69 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | -12.32 Mn |
| Sep 30, 2021 | -10.83 Mn |